TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7864916

Group type: EXPERIMENTAL
Intervention: Laser vaporization treatment
Number of subjects: 365

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 365
Study: 3513411

Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia with 24 hours of bed rest
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia with mobilization
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standardised spinal anaesthesia with 24 hours of bed rest (surgeon's choice)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Standardised spinal anaesthesia
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Patients predisposed to headache, lumbar pain, and visual disturbances
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: All newly developed symptoms
Number of subjects: 158
Study: 31506240

Group type: EXPERIMENTAL
Intervention: Handwriting exercise (4-week duration using a handwriting practice book)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no handwriting exercise)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Handwriting exercise
Number of subjects: 46
Study: 29861245

Group type: EXPERIMENTAL
Intervention: Pilates-based mat exercises (twice per week, 60-min per session for 16 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 26605991

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once daily
Number of subjects: 950

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 950
Study: 26182769

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 148

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 148
Study: 24050312

Group type: EXPERIMENTAL
Intervention: MEDI-528 (30, 100, 300 mg) every 2 weeks for 24 weeks
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: MEDI-528 (combined)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: MEDI-528 (30 mg, 100 mg, 300 mg)
Number of subjects: 329
Study: 21048530

Group type: EXPERIMENTAL
Intervention: Whole blood real-time PCR assay
Number of subjects: 219

Group type: COMPARATOR
Intervention: Plasma PCR assay
Number of subjects: 219
Study: 18512199

Group type: EXPERIMENTAL
Intervention: Participation in Diabetes DMP
Number of subjects: 3546

Group type: COMPARATOR
Intervention: Non-participation in Diabetes DMP
Number of subjects: 3546
Study: 16556138

Group type: EXPERIMENTAL
Intervention: Etidronate treatment (oral, prior to sleep on dialysis days for 23 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no etidronate treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Etidronate treatment
Number of subjects: 21
Study: 14986872

Group type: EXPERIMENTAL
Intervention: Enhanced version of NIDA standard HIV Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Focused Intervention based on a cognitive thought‐mapping model
Number of subjects: 0
Study: 10630936

Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control of the proximal segment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in the mandibular plane
Number of subjects: 0
Study: 9004050

Group type: EXPERIMENTAL
Intervention: Reduction of 33-40% in daily dosage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reduction of 60-66% in daily dosage
Number of subjects: 30

Group type: COMPARATOR
Intervention: No reduction (control group)
Number of subjects: 30
Study: 8207316

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 3430969

Group type: EXPERIMENTAL
Intervention: Hypothermic dialysis (blood temperature 25 degrees C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control procedure (blood temperature 35 degrees C)
Number of subjects: 9
Study: 29546401

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28104903

Group type: EXPERIMENTAL
Intervention: Traction therapy with the Saunders device
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 174
Study: 26025383

Group type: EXPERIMENTAL
Intervention: TEAS treatment (30 minutes each day for 4 consecutive days during HDBR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (4 days HDBR without countermeasures)
Number of subjects: 14
Study: 23925377

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cell (MSC) therapy, administered as three transfusions at 1-month intervals over 12 months.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control group), administered in parallel to six patients.
Number of subjects: 13
Study: 21936892

Group type: EXPERIMENTAL
Intervention: EGML (2 g/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GCE (2 g/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (starch, 2 g/day)
Number of subjects: 86
Study: 17625035

Group type: EXPERIMENTAL
Intervention: Nasal polyposis patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nasal polyposis patients vs Control subjects
Number of subjects: 28
Study: 16608033

Group type: EXPERIMENTAL
Intervention: Lamivudine plus thymosin alpha1 therapy postoperatively
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hepatectomy only (Control)
Number of subjects: 33
Study: 14552498

Group type: EXPERIMENTAL
Intervention: Skills Training (ST) for 3 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Customary Outpatient Care (CC)
Number of subjects: 92
Study: 12889398

Group type: EXPERIMENTAL
Intervention: Double-layer air-cell overlay
Number of subjects: 82

Group type: COMPARATOR
Intervention: Single-layer air-cell overlay
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 82
Study: 10465485

Group type: EXPERIMENTAL
Intervention: Two-level Mittelmeier osteotomy (Group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lateral closed wedge high tibial osteotomy using AO/ASIF L-plate (Group B)
Number of subjects: 63
Study: 8609324

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone, 5 mg/kg body weight in 30 min followed by 1,200 mg over 24 h
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study: 1921738

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg daily for 24 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6311914

Group type: EXPERIMENTAL
Intervention: Multiple-dose IFN-alpha 2 (11.4 X 10(6) IU four times per day for four days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: One daily treatment of IFN-alpha 2 (42.8 X 10(6) IU once per day for five days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both dosage regimens of IFN-alpha 2
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2
Number of subjects: 2
Study: 3885670

Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 (PGE2) vaginal suppositories
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intranasal oxytocin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combined method of 3 mg PGE2 vaginal suppositories alternating with intranasal oxytocin
Number of subjects: 300
Study: 30451392

Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parents of participants in the immediate intervention group
Number of subjects: 30
Study: 28272029

Group type: EXPERIMENTAL
Intervention: Intraoperative Continuous Intestinal Loop Warming (ICLW)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no ICLW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 25819645

Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision (PFN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Expanded port site incision (EPS)
Number of subjects: 51
Study: 24139548

Group type: EXPERIMENTAL
Intervention: Telemedicine treatment at home using a video conference system with monitoring equipment (spirometer, thermometer, pulse oximeter) and 24/7 online access to the hospital.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment at the hospital.
Number of subjects: 0
Study: 20722752

Group type: EXPERIMENTAL
Intervention: NRTI-sparing arm (zidovudine/lamivudine+efavirenz)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Protease inhibitor-sparing arm (lopinavir/ritonavir+efavirenz)
Number of subjects: 63
Study: 19050084

Group type: EXPERIMENTAL
Intervention: 150 microg x kg(‐1) morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 16550736

Group type: EXPERIMENTAL
Intervention: Content of capsule sprinkled on applesauce (Medikinet retard 20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intact capsule (Medikinet retard 20 mg)
Number of subjects: 12
Study: 12569218

Group type: EXPERIMENTAL
Intervention: Community-based (CB) program
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Home-based (HB) program
Number of subjects: 34
Study: 10843243

Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in MC or mild MesP nephrosis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in steroid resistant, MesP nephrosis
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peritubular capillary flow in nephrosis with FSGS
Number of subjects: 51
Study: 9386883

Group type: EXPERIMENTAL
Intervention: Brief physician advice (5 minutes)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Two 30-minute sessions with a physician using cognitive behavioural strategies
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Two 30-minute sessions with a nurse practitioner using identical strategies
Number of subjects: 159

Group type: COMPARATOR
Intervention: Overall reduction in quantity and frequency of drinking
Number of subjects: 159
Study: 8383518

Group type: EXPERIMENTAL
Intervention: 100 mg rac-atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg (S)-atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50 mg (R)-atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (S)-atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (R)-atenolol
Number of subjects: 12
Study: 2876770

Group type: EXPERIMENTAL
Intervention: BCG (Tice) injected intrapleurally between days 6 and 12 postoperatively, with isoniazid given orally for 12 weeks.
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group received saline injected intrapleurally.
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: BCG treatment.
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: BCG treatment in pneumonectomized patients.
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: BCG treatment vs placebo in lobectomies.
Number of subjects: 441
Study: 31238312

Group type: EXPERIMENTAL
Intervention: Nomogram developed based on 8 identified risk factors for pancreatic stones in CP patients.
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Cumulative rates of pancreatic stones after the onset of CP and after the diagnosis of CP.
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Risk factors identified through Cox proportional hazards regression model.
Number of subjects: 2153
Study: 29880427

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 20 µg/kg/min) and Nitroglycerin (0.5 to 3 µg/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milrinone (loading dose of 50 µg/kg over 10 minutes, followed by maintenance dose of 0.25 to 0.75 µg/kg/min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Dobutamine/Nitroglycerin and Milrinone)
Number of subjects: 40
Study: 27771263

Group type: EXPERIMENTAL
Intervention: Hydrodistention with joint manipulation under interscalene block
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injection
Number of subjects: 121
Study: 24164167

Group type: EXPERIMENTAL
Intervention: Traditional stainless steel crown (SSC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aesthetic crown
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control teeth (not restored)
Number of subjects: 76
Study: 22622705

Group type: EXPERIMENTAL
Intervention: Auditory training for 4 weeks, 1 hour a day, 5 days a week using both cochlear implant and hearing aid devices.
Number of subjects: 7
Study: 20820984

Group type: EXPERIMENTAL
Intervention: Docetaxel 45 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Irinotecan 180 mg/m² with bolus/44-h infusion of 5-Fluorouracil/leucovorin (5-Fu/Lv)
Number of subjects: 78
Study: 18848791

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation without sapheno-femoral junction ligation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Endovenous laser ablation with sapheno-femoral junction ligation
Number of subjects: 43
Study: 16644021

Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS) with a positivity threshold of 9.5/30
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Risk markers identified through multivariate risk analysis
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: EPDS score >10
Number of subjects: 815
Study: 14654262

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10719390

Group type: EXPERIMENTAL
Intervention: Specialist diabetes education program led by specialists and a dietician
Number of subjects: 75

Group type: COMPARATOR
Intervention: General practice diabetes education program performed by a doctor's assistant
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Evaluated support program addressing psychosocial impediments
Number of subjects: 75
Study: 9110111

Group type: EXPERIMENTAL
Intervention: Propantheline bromide, 64.3 (+/‐ 21.8) mg/day for 7 days, followed by 30 mg orally before repeat tilt-table testing.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propantheline bromide treatment
Number of subjects: 16
Study: 1514336

Group type: EXPERIMENTAL
Intervention: Single-dose spinal anaesthesia with 3 ml of plain 0.5% bupivacaine (SDSA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia using a 32- or 22-gauge catheter with a bolus of 1.0 ml or 0.5 ml of plain 0.5% bupivacaine followed by an infusion at a rate of 2 ml/h (CSA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia (CSA group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-dose spinal anaesthesia (SDSA group)
Number of subjects: 40
Study: 3906163

Group type: EXPERIMENTAL
Intervention: Soybean phospholipid (18 g daily for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31230119

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid injection (3 injections weekly starting immediately after ORIF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no injection after ORIF)
Number of subjects: 40
Study: 28045979

Group type: EXPERIMENTAL
Intervention: Intensive diabetes self-management education (DSME) programme for six months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional education for six months
Number of subjects: 118
Study: 26345817

Group type: EXPERIMENTAL
Intervention: Adherence to GOLD guidelines (intervention group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Standardized management (intervention group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no adherence to GOLD guidelines)
Number of subjects: 102
Study: 23297711

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valsartan (80-320 mg/day)
Number of subjects: 20
Study: 22067476

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 108
Study: 17614243

Group type: EXPERIMENTAL
Intervention: Mandatory treatment for repeat DUI offenders
Number of subjects: 233
Study: 16925757

Group type: EXPERIMENTAL
Intervention: Docetaxel (70 mg/m² intravenously on day 2 every 21 days) and estramustine (3 x 280 mg/day oral for 5 consecutive days) with dexamethasone (16 mg total daily dose for 5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Estramustine (3 x 140 mg/day oral for 3 consecutive days) with dexamethasone (16 mg total daily dose for 3 days)
Number of subjects: 72
Study: 12924097

Group type: EXPERIMENTAL
Intervention: Inactivated split trivalent influenza vaccine (IIV), administered parenterally
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Live cold‐adapted reassortant trivalent influenza vaccine (LIV), administered intranasally
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combination of both vaccines
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 10753249

Group type: EXPERIMENTAL
Intervention: Plant stanol ester margarine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 81
Study: 8777253

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of taxoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy before surgery
Number of subjects: 0
Study: 1576325

Group type: EXPERIMENTAL
Intervention: Terfenadine after a high fat breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terfenadine while fasting
Number of subjects: 0
Study: 2408319

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 19

Group type: COMPARATOR
Intervention: Donor plasma
Number of subjects: 19
Study: 30440099

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied during surgical procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (received no PRP injection)
Number of subjects: 100
Study: 30360965

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg (via two 70 mg injections) every 4 weeks for 12 weeks
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 27449267

Group type: EXPERIMENTAL
Intervention: Applied Behavior Analysis (ABA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Modified Sequential Oral Sensory Approach (M-SOS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Applied Behavior Analysis (ABA) after M-SOS
Number of subjects: 6
Study: 24586031

Group type: EXPERIMENTAL
Intervention: Sequential therapy - 20 mg omeprazole and 1 g amoxicillin for 5 days, followed by 20 mg omeprazole, 500 mg clarithromycin and 500 mg tinidazole for the successive 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14 day concomitant therapy - 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid therapy - 20 mg omeprazole and 1 g amoxicillin for 7 days, followed by 20 mg omeprazole, 1 g amoxicillin, 500 mg clarithromycin and 500 mg tinidazole for the successive 7 days
Number of subjects: 0
Study: 22157137

Group type: EXPERIMENTAL
Intervention: Adolescent Asthma Action program
Number of subjects: 261
Study: 20019107

Group type: EXPERIMENTAL
Intervention: CE-MRA at 1.5T
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CE-MRA at 3T
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TOF-MRA at 1.5T
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CE-MRA at 1.5T and 3T
Number of subjects: 58
Study: 17942471

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 or 10 g/day) and rhGH (0, 3, or 5 microg/kg/day) for 16 weeks
Number of subjects: 112
Study: 15020610

Group type: EXPERIMENTAL
Intervention: Three to four courses of high-dose cytarabine (HDAC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: One course of high-dose cytarabine (HDAC) followed by alternative intensive consolidation therapy
Number of subjects: 48
Study: 11937116

Group type: EXPERIMENTAL
Intervention: Dienogest, 1 mg tablet daily for 16 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Decapeptyl, 3.75 mg IM injection every 4 weeks for 16 weeks
Number of subjects: 142
Study: 9523365

Group type: EXPERIMENTAL
Intervention: Hypoxic ventilatory response (HVR) during severe hypoxia (PETO2 from 60 to 35 mm Hg) in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alveolar ventilation while breathing air in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PETO2 while breathing air in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PETCO2 while breathing air in PD patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HVR during minor hypoxia (PETO2 from 100 to 60 mm Hg)
Number of subjects: 24
Study: 8994987

Group type: EXPERIMENTAL
Intervention: Conventional CO2 pneumoperitoneum
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mechanical abdominal wall lift (AWL) method with minimal CO2 insufflation
Number of subjects: 25
Study: 2017647

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intramuscular dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin (standard regimen)
Number of subjects: 0
Study: 7038842

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU and BCNU
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31847246

Group type: COMPARATOR
Intervention: LC-CON
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: LC-HIIT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: LC-MICT
Number of subjects: 58
Study: 28372791

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Open plating
Number of subjects: 107
Study: 23716985

Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) at a dosage of 2.52 g/d (1 sachet of 1.26 g 2 times a day) for 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) at the same dosage for 4 weeks
Number of subjects: 84